Characterization of anandamide-induced tolerance: Comparison to Δ9-THC-induced interactions with dynorphinergic systems

Drug and Alcohol Dependence

Volumn 45, Issue 1-2, 1997, Pages 39-45

  Welch, Sandra P ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

9 THC; Anandamide; CP55,940; Dynorphins; Tolerance

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID RECEPTOR; DRONABINOL; DYNORPHIN; OPIATE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TOLERANCE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAIL FLICK TEST;

ANALGESICS; ANIMALS; ARACHIDONIC ACIDS; CANNABINOIDS; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; DYNORPHINS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SPINAL; MICE; NALTREXONE; NARCOTIC ANTAGONISTS; PAIN MEASUREMENT; POLYUNSATURATED ALKAMIDES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TETRAHYDROCANNABINOL;

ANIMALIA;

EID: 0030975023     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(97)01342-2     Document Type: Article

References (37)

1. Butelman, E.R., France, C.P. and Woods, J.H. (1995) Agonist and antagonist effects of dynorphin A (1-13) in a thermal antinociception assay in rhesus monkeys. J. Pharmacol. Exp. Ther. 275, 374-380.
2. Chavkin, C., James, I. and Goldstein, A. (1982) Dynorphin is a specific endogenous ligand for the kappa opioid receptor. Science 215, 413-415.
3. Claye, L.H., Unterwald, E.M., Ho, A. and Kreek, M.J. (1996) Both dynorphin A (1-17) and 〈Des-tryl〉dynorphin A (2-17) inhibit adenylyl cyclase activity in rat caudate putamen. J. Pharmacol. Exp. Ther. 277, 359-365.
4. D'Amour, F.E. and Smith, D.L. (1941) A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72, 74-79.
5. Devane, W.A., Hanus, L., Breuer, A., Pertwee R.G., Stevenson, L.A., Griffin. G., Gibson, D., Mandelbaum, A., Etinger, A. and Mechoulam, R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
6. 5]-enkephalin from dynorphin A (1-8) by rat central nervous tissue in vitro. J. Neurochem. 54, 1379-1385.
7. Dunnett, C.W.(1955) A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50, 1096-1121.
8. 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J. Pharmacol. Exp. Ther. 271, 1383-1390.
9. Felder, C.C., Briley, E.M., Axelrod, J., Simpson, J.T., Mackie, K. and Devane, W.A. (1993) Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA 90, 7656-7660.
10. 9-tetrahydrocannabinol. Brain Res. 697, 83-90.
11. 9 tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 272, 699-707.
12. Fride, E. and Mechoulam, R. (1993) Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 231, 313-314.
13. Harris, L.S. and Pierson, A.K. (1964) Some narcotic antagonists in the benzomorphan series. J. Pharmacol. Exp. Ther. 143, 141-148.
14. Hollt, V. (1986) Opioid peptide processing and receptor selectivity. Annu. Rev. Pharmacol. Toxicol. 26, 59-77.
15. Hylden, J.L.K. and Wilcox, G.L. (1983) Pharmacological characterization of substance P-induced nociception in mice: Modulation by opioid and noradrenergic agonists at the spinal level. Eur. J. Pharmacol. 67, 313-404.
16. Lichtman, A.H. and Martin, B.R. (1991a) Spinal and supraspinal mechanisms of cannabinoid-inducedantinociception. J. Pharmacol. Exp. Ther. 258, 517-523.
17. Lichtman, A.H. and Martin, B.R. (1991b) Cannabinoid-induced antinociception is mediated by a spinal alpha2-noradrenergic mechanism. Brain Res. 559, 309-314.
18. Litchfield, ST. and Wilcoxon. F.(1949) A simplified method of evaluating dose effect experiments. J. Pharmacol. Exp. Ther. 96, 99-113.
19. Mackie, K., Devane, W.A. and Hille, B. (1993) Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44, 498-503.
20. Mechoulam, R., Hanus, L. and Martin, B.R. (1994) Search for endogenous ligands of the cannabinoid receptor. Biochem. Pharmacol. 48, 1537-1544.
21. Nylander, I., Tan-No, K., Winter, A. and Silberring, J. (1995) Processing of prodynorphin-derived peptides in striatal extracts. Identification by electrospray ionization mass spectrometry linked to size-exclusion chromatography. Life Sci. 57, 123-129.
22. Pertwee, R., Griffin, G., Hanus, L. and Mechoulam, R. (1994) Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. Eur. J. Pharmacol. 259, 115-120.
23. Pertwee, R.G., Stevenson, L.A. and Griffin G. (1993) Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br. J. Pharmacol. 110, 1483-1490.
24. 9-THC in the spinal cord. Brain Res. 689, 157-158.
25. Pugh, G.J., Mason, D.J., Combs, V. and Welch, S.P. (1997) Involvement of dynorphin B in the antinociceptive effects of the cannabinoid, CP55,940, in the spinal cord. J. Pharmacol. Exp. Ther. (in press).
26. 9-THC and morphine in the spinal cord. J. Pharmacol. Exp. Ther. 279, 608-616.
27. Showalter, V.M., Compton, D.R., Martin, B.R. and Abood, M.E. (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective-ligands. J. Pharmacol. Exp. Ther. 278, 989-999.
28. Smith, P.B., Compton, D.R., Welch, S.P., Razdan, R.K., Mechoulam, R. and Martin, B.R. (1994a) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270, 219-227.
29. 9 tetrahydrocannabinol and kappa opioids in mice. J. Pharmacol. Exp. Ther. 268, 1381-1387.
30. Song, Z.H. and Takemori, A.E. (1991) Involvement of spinal kappa opioid receptors in the antagonistic effect of dynorphins on morphine antinociception. Life Sci. 48, 1447-1453.
31. Tseng, L.F. and Collins, K.A. (1993) Spinal involvement of both dynorphin A and Metenkephalin in the antinociception induced by intracerebroventricularly administered bremazocine but not morphine in the mouse. J. Pharmacol. Exp. Ther. 266, 1430-1438.
32. 9-THC precipitated by a cannabinoid receptor antagonist. Eur. J. Pharmacol. 280, R13-R15.
33. Welch, S.P. (1993) Modulation of cannabinoid-induced antinociception by norbinaltorphimine, but not N, N-Diallyl-Tyrosine-Aib-Phenylalanine-Leucine, ICI 174,864 or naloxone in mice. J. Pharmacol. Exp. Ther. 265, 633-640.
34. 9-THC-induced antinociception. J. Pharmacol. Exp. Ther. 272, 1235-1244.
35. Welch, S.P. and Stevens, D.L. (1992) Antinociceptive activity of intrathecallyadministered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther. 262, 10-18.
36. Welch, S.P., Thomas, C. and Patrick, G.S. (1995b) Modulation of cannabinoid-induced antinociception following intracerebroventricular versus intrathecal administration to mice: Possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 272, 310-321.
37. Yaksh, T.L. (1981) The antinociceptive effects of the intrathecally administered levonantradol and desacetyllevonantradol in the rat. J. Clin. Pharmacol. 21, 334S-340S.